Antifungal Treatment Market Information, By Drugs Class (Azoles,
Pyrimidines, Echinocandins, Polyenes, Allylamines, And Others), By Therapeutic
Indication (Systemic, Candidiasis, Coccidioidomycosis, Cryptococcosis, And
Prophylactic), By Pathogen (Candida, Aspergillus, Cryptococcus, Coccidioides
Immitis, Zygomycetes, Trichophyton, And Others), And By End Users (Hospitals
& Clinics, Dermatology Clinics, And Others) - Global Forecast Till 2023
Market Analysis
The global Antifungal
Treatment Market is predicted to touch USD 19,558.0 million at a 4.61% CAGR over
the forecast period (2017-2023), states the latest Market Research Future
(MRFR) report. Fungal infections in the body result from unclean and unhygienic
environments where fungal agents thrive. Such agents grow by spreading spores,
which causes skin infection subsequently or when fungal infections are inhaled
(systematic). Antifungal drugs or treatment are substances that selectively
acts against the fungal pathogen in the fungal infection treatment.
Allylamines, polyenes, echinocandins, pyrimidines, and azoles are the most
widely used antifungal treatments.
Various factors are propelling
the antifungal treatment market growth. Some of these factors, according to the
Market Research Future report, include rising number of patients with fungal
diseases, rising geriatric population, growing awareness regarding different
fungal infections, rising corporate and government initiatives, and rise in
population which come in contact with infections and resistant fungal strains.
Additional factors pushing market growth include the weakened immune system,
rising disposable income, increased investments in research and development
activities, private-public partnership agreements in the pharmaceutical sector
to develop new and effective antifungal drugs, and growing demand for over the
counter (OTC) drugs to treat skin infections.
On the contrary, availability of
conventional therapies and generic drugs for fungal infections, allergic
reaction to specific antifungal drugs, and government regulations in the
pharmaceutical industry are factors that may deter the antifungal treatment
market growth over the forecast period.
Market Segmentation
The MRFR report offers a wide
segmental analysis of the antifungal treatment market on the basis of drug
class, therapeutic indication, pathogen, and end users.
Based on drug class, the
antifungal treatment market is segmented into allylamines, polyenes,
echinocandins, pyrimidines, azoles, and others. Of these, the azoles segment
will have the largest share in the market over the forecast period. Azoles are
used for treating ocular fungal infections, systemic candidiasis, blastomycosis,
and candidemia.
Based on therapeutic indication,
the antifungal treatment market is segmented into cryptococcosis,
coccidioidomycosis, candidiasis, and systemic. Of these, the systemic segment
will dominate the market over the forecast period.
Based on pathogens, the
antifungal treatment market is segmented into trichophyton, zygomycetes,
coccidioides immitis, cryptococcus, aspergillus, candida, and others.
Based on end user, the
antifungal treatment market is segmented into dermatology clinics, hospitals
and clinics, and others.
Browse Complete Report : https://www.marketresearchfuture.com/reports/antifungal-treatment-market-1628
Regional Analysis
By region, the antifungal
treatment market report covers the latest trends and growth opportunities
across the Americas, the Asia Pacific, Europe, and the Middle East and Africa.
Of these, the Americas, particularly North America, will lead the market over the
forecast period. This is owing to the rising incidences of patients in this
region with fungal infections, developed healthcare infrastructure, and quick
adoption of new antifungal treatments.
The antifungal treatment market
in Europe will have the second-largest share in the market over the forecast
period. Most companies in Europe are emphasizing on R&D of antifungal drugs
that in turn, is pushing market growth. These companies are getting government
funding that is favoring the market growth in this region.
The antifungal treatment market
in the APAC region is predicted to grow at the fastest pace over the forecast
period. This is owing to the increasing awareness regarding available fungal infection
treatments, rising healthcare expenditure, rising adoption of new medical
practices, and developing healthcare infrastructure.
The antifungal treatment market
in the Middle East and Africa is predicted to have a slow growth over the
forecast period. This is owing to limited access to healthcare facilities and
lack of awareness regarding antifungal treatments.
Key Players
Leading players profiled in the
antifungal treatment market report include Bayer AG (Germany), Astellas
(Japan), Merck & Co., Inc. (U.S), Sanofi (France), Pfizer Inc. (U.S), and
Novartis AG (Switzerland), among others. Key players have incorporated
strategies such as technology launch, expansion, partnership, collaboration,
and acquisition for gaining a competitive advantage in the market.
March 2019: Pharmbio Korea has
signed a deal with BioSynectics for creating an antifungal treatment,
PBK-1819-2. The company will use the nanotechnology of BioSynectics to create
the drug. The nano-conversion technology will offer an array of perks such as
lower side effects, dietary as well as post-diastolic deviation, and improved
bioavailability.
No comments:
Post a Comment